Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- Chuikyo’s Drug Pricing Panel to Continue Discussions on Penalties and Actions against Novartis
September 11, 2014
- Drug Costs Made Up 21.9% of Japan Healthcare Spending in FY2011: MHLW
September 11, 2014
- MLHW to Issue Development Request for Vaccines that Require Fewer Doses
September 11, 2014
- New Minister Eager to Keep 30% Deduction Cap for R&D Tax Credit System
September 10, 2014
- Jichi Medical University President Seen as Prime Candidate for Japan NIH Head
September 10, 2014
- Takeda Chairman Removed from Competitiveness Panel
September 9, 2014
- Editor’s Pick: Five Healthcare News Headlines for August 25 – September 5
September 8, 2014
- Two Female Lawmakers Named New Senior Vice Health Ministers
September 8, 2014
- PAFSC’s Second Committee Backs Approval of Nobelpharma’s Anticancer Drug, MSD’s Hepatitis C Treatment
September 8, 2014
- PAFSC’s First Committee Supports Approval of Lixiana’s Additional Indications
September 5, 2014
- New Health Minister Plays it Safe, Promises to Follow Cabinet Decision on NHI Price Revision Frequency
September 5, 2014
- Industry on Alert as Reformist Shiozaki Tapped as New Health Minister
September 4, 2014
- PFSB Issues Notification on Submission of Package Inserts Under New Act
September 4, 2014
- LDP’s Niwa Says Treatment of Post-HPV Vaccine Adverse Reactions Top Priority
September 3, 2014
- MHLW to Consider Another Punishment or Action against Novartis Pharma: Minister
September 3, 2014
- Yasuhisa Shiozaki Tapped as New Health Minister
September 3, 2014
- MHLW Will Discuss Freezing NHI Prices of Essential Drugs if Industry Requests It: MHLW Official Nakai
September 3, 2014
- MOF Official Unami Urges Full-Scale NHI Price Revision upon Next Sales Tax Hike
September 2, 2014
- METI to Request 20% Increase in Budget for Promotion of Science and Technology: FY2015 Budget Request
September 2, 2014
- MHLW to Reinforce Follow-Up Surveys on HPV Vaccine Recipients
September 1, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…